Mark Bamford

Director and Discovery Partnership Leader at Glaxo SmithKline

About Glaxo SmithKline

GlaxoSmithKline (http://www.gsk.com/) – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  ‘Discovery Partnerships with Academia’ (DPAc) is a new approach to early drug discovery. The concept is simple but powerful: bring together the insight and creativity of the academic world with the drug discovery expertise of GlaxoSmithKline (GSK) to establish truly integrated partnerships that can translate innovative research into medicines that benefit patients.  For further information please visit http://www.dpac.gsk.com/.

About Mark BamfordBamford

Mark is a DPAc leader with expertise in medicinal chemistry and drug discovery. He has extensive project leadership experience, having progressed multiple projects to significant milestones—across a range of targets and therapy areas—from hit generation to candidate selection and beyond. Mark is a founding member of DPAc, and has initiated a number of DPAc projects and was a project leader of the first DPAc project to achieve candidate selection. Mark is a synthetic organic chemist by training, with a background as a practicing medicinal chemist at GSK and legacy organizations.

Share this page: